• / Free eNewsletters & Magazine
  • / My Account
Home>Paul Larson

Paul Larson

  1. All
  2. Morningstar Articles
  3. Videos
  4. Investing
  1. The Ones That Got Away

    Morningstar's Matt Coffina looks back on some recent missed opportunities and what he learned from them--also, a couple of stocks he's glad he avoided.

  2. Where Will Growth Come From?

    With dividend yields below long-run historical norms and the market overall looking pricey, growth in companies' intrinsic values will be key for stock investors, says Morningstar's Matt Coffina.

  3. Larson's Strategies for Excess Returns

    StockInvestor editor Paul Larson discusses the importance of investing in companies that can compound their intrinsic values, buying on the cheap, avoiding stop-loss orders, and more.

  4. How to Protect From Black Swans and Black Boxes

    The financial crisis proved that tumultuous events can and do happen, and investors need to keep a long-term perspective in a market that is incredibly short-term focused, says StockInvestor editor Paul Larson .

  5. A Rare Time for Wide-Moat Stocks?

    StockInvestor editor Paul Larson details recent changes to Morningstar's Wide Moat Focus Index, noting how the rally in wide-moat names could have them more fairly priced than lower-quality stocks.

  6. MLPs: High-Quality Income Generators

    Tax advantages and economic moats allow master limited partnerships to offer investors much more than just high yields, says Morningstar's Paul Larson .

  7. New Year, New Moat Ratings for These Stocks

    Competitive advantages improved for one health-care firm, while a spin-off at another narrowed its moat, says Morningstar's Paul Larson in his discussion on recent moat-rating upgrades and downgrades.

  8. Visa's Growth Story Is Not Broken

    Recent decelerating revenue growth has disappointed investors but is a temporary phenomenon, says Morningstar StockInvestor editor Matt Coffina.

  9. A Rare, Wide-Moat Find in a Market With Few Values

    Investors concerned with Express Scripts' integration of Medco are overlooking the firm's long-term potential to benefit from an increased focus on health-care cost-cutting, says Morningstar StockInvestor editor Matt Coffina.

  10. The Market Is Richly Valued--Should You Worry?

    Although a drawdown in the short term is a real possibility, investors should still see a 4.5% to 6% real return over the long run, says Morningstar's Matt Coffina.

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.